Clinical trial
Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma
NCT00003719 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00003719 |
|---|---|
| Title | Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma |
| Official title | Phase II Evaluation of Irinotecan (CPT-11) in Previously Treated Advanced Sarcomas |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 27 |
| Start date | Jul 1, 1997 |
| First posted | Apr 14, 2004 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: